Sanofi has signaled that it will raise U.S. list prices on a subset of its branded medicines starting January 1, 2026, as part of an industry-wide plan affecting at least 350 products. According to data from 3 Axis Advisors, this cohort of branded drugs includes established vaccines and specialty treatments, with the industry median list-price increase projected at roughly 4%. Although Sanofi has not disclosed the exact number of its vaccines or therapies slated for adjustment, the company’s participation underscores its intent to align price strategies with peers such as Pfizer and Novartis despite political scrutiny over rising drug costs.

The planned increases represent changes to list prices and do not reflect confidential rebates, volume discounts or pharmacy benefit manager agreements that can substantially reduce the net cost to insurers and government payers. Industry analysts estimate that net price growth for major pharmaceutical manufacturers has remained below 2% annually over the past two years once rebate arrangements are factored in. Sanofi’s finance team has cited rising research and manufacturing costs—particularly for next-generation immunology and vaccine platforms—as a key driver for maintaining list-price momentum.

Sanofi is among 14 manufacturers that have entered pricing agreements with the U.S. government to secure discounted rates for certain drugs sold to Medicare beneficiaries and Medicaid programs. These negotiated concessions cover a limited portfolio of high-cost medications, but Sanofi will still pursue list-price increases on other branded products not subject to government negotiation. Industry observers note that while negotiated cuts apply to single‐digit portions of a company’s revenue base, list‐price hikes on broader portfolios remain critical to offsetting margin pressures from R&D investments and biosimilar competition.